Announcements

Conference: The 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026)
Organization: European Association for the Study of Diabetes
Date: 28 September–2 October 2026
Place: Allianz MiCo—Milan Convention Centre, Milan, Italy
Booth Number: L.03

The 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) is set to take place from 28 September to 2 October 2026 at the Allianz MiCo - Milan Convention Centre in Milan, Italy. This global diabetes conference will convene thousands of delegates from all across the globe to explore the latest advancements in diabetes research, treatment, and care.​

The scientific programme will feature hundreds of presentations, including keynote lectures, symposia, and oral sessions, offering insights into cutting-edge developments in both basic and clinical diabetes research. Attendees will have the opportunity to engage with leading experts, fostering collaboration and knowledge exchange across the international diabetes community.​

The Organization of this conference, the European Association for the Study of Diabetes e.V. (EASD), is a membership-based academic non-profit organization. It was founded in 1965 and is based in Düsseldorf, Germany. The aims of EASD are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.

The following open access journals will be represented:

• Biomedicines;
• Diabetology;
• JCM;
• Medicina;
• Endocrines;
• IJERPH;
• Antioxidants;
• Biomolecules;
• Epidemiologia;
• JMAHP;
• Nutrients;
• Trends in Public Health.

If you are attending the 62nd EASD Annual Meeting, we invite you to visit us at our booth #L.03. Our representatives will be available to discuss publishing opportunities, the benefits of open access, and answer any questions that you may have.

Join us in Milan to discover what is next in diabetes science and care! For more information about the conference, please visit its official website at https://www.easd.org/annual-meeting/easd-2026/.

We are honored to announce that Prof. Dr. William Gerwick will serve as the Chair of the 2026 Tu Youyou Award Committee.

A world-renowned authority in marine natural products chemistry and pharmacology, Professor Gerwick is a Distinguished Professor at both the Scripps Institution of Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego (UCSD). His pioneering work at the intersection of ocean sciences and drug discovery makes him a fitting leader for an award centered on transformative medicinal breakthroughs.

Under Professor Gerwick’s stewardship, the 2026 Tu Youyou Award Committee will focus on recognizing innovative and impactful research in natural products chemistry and medicinal chemistry, particularly work with the potential to drive meaningful advances in both scientific understanding and human health.

To provide further insight into his perspectives, we include below an interview with Professor Gerwick, in which he reflects on his scientific journey, his views on the field, and his vision for the Tu Youyou Award.

A Conversation with the Chair

1. Could you please introduce yourself and your research journey?

My research focuses on the natural products of marine algae and cyanobacteria, their application in medicine, their biosynthesis using genomic approaches, and innovative methods in the structure elucidation of natural products.

I received my BS degree from the University of California at Davis, my PhD from the University of California at San Diego, and conducted postdoctoral work at the University of Connecticut. After a couple of years in a junior faculty position at the Department of Chemistry at the University of Puerto Rico, I spent 21 years as Professor of Pharmacy at Oregon State University. In 2005, I returned to my PhD institution at the Scripps Institution of Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences at UC San Diego, where I am currently a Distinguished Professor of Oceanography and Pharmaceutical Sciences.

Throughout my career, I have been dedicated to advancing the field through both leadership and mentorship. I have served as president of the American Society of Pharmacognosy, chaired and co-chaired several major research conferences, and served as an associate editor for the Journal of Natural Products. I am a Fellow of the American Association for the Advancement of Science (AAAS) and of the American Society of Pharmacognosy. I have trained over 100 doctoral and postdoctoral students, and my research group has published nearly 500 papers and more than 25 patents on topics in the natural product sciences and medicinal chemistry.

2. What motivated you to accept the role of Chair of the 2026 Tu Youyou Award Committee?

Of course, I am a huge supporter of all awards that are given in recognition of excellent scientific research, and especially so in the natural products sciences and medicinal chemistry. However, this award is truly special in that it recognizes scientific excellence as well as impact, and is given in the name of an individual, Tu Youyou, who clearly had many challenges along the path to reach the pinnacle of her success. Not only was she the first Chinese person to win a Nobel prize in this area, but she was also the first Chinese woman to receive a Nobel prize, and this was achieved without graduate education in China or elsewhere. It’s a true testament to what can be achieved by hard work, determination, and vision. To read the history of her extraordinary approach to discovering novel antimalarial compounds from Traditional Chinese Medicine is truly inspirational. It is, therefore, the inspiration provided by the extraordinary life and career of Tu Youyou that motivated me to accept the Chair of the Award Committee for 2026.

3. How do you view the role of natural products chemistry and medicinal chemistry in today’s scientific landscape, and what major advances over the past decade have shaped this field?

A quite remarkable integration of fields is currently transforming natural products science and medicinal chemistry. In natural products, we are seeing integration of different omics methods, from metabolites to proteins to nucleic acids. Sophisticated biological and pharmacological approaches are driving the discovery of exquisitely potent and selective natural products. Advances are being made to integrate molecular-level recognition of natural products with chemical ecological studies, and sophisticated methods of structure determination using Artificial Intelligence or pioneering new tools such as microED are being applied with increasing frequency. High-level synthetic methodologies, such as protecting group-free synthetic routes, are enhancing medicinal chemistry, accelerating the identification of lead molecules with attractive pharmaceutical properties at an increasing pace.

4. How do you consider the balance between fundamental discovery (e.g., new molecules or mechanisms) and practical impact (e.g., therapeutic applications)?

Many individuals are excellent scientists and mentors, and have essential roles in developing our culture that values science and the scientific method. It should also be pointed out that not all scientific discoveries are going to have a broad societal impact, but they are nevertheless critical to the overall body and structure of science. But it is a truly remarkable individual who makes a key scientific discovery, recognizes its potential value to society in general, and then has the skills and determination to bring it forward as a useful product. That was the type of person the Tu Youyou is, and that is the type of person who is honored by the prize in her name.

5. What do you see as the key challenges or opportunities currently facing the field?

We are on the crux of an amazing revolution in many of the sciences, including natural products and medicinal chemistry; the purposeful application of Artificial Intelligence to solving many of the difficulties involved in the search for new pharmaceuticals from Nature. AI is transforming how we select organisms for study, what pharmaceutical targets to go after, rapidly resolving the chemical structures of new compounds, identifying efficient routes to their chemical synthesis, understanding their molecular mechanisms of action, and finally, designing their clinical application. The role of people in these pursuits is changing. Increasingly, the human role will be providing overall vision: what can we do? What should we do? And it is important to remember that AI is providing hypotheses, not truth. Scientists with expert domain knowledge will be critical for discerning the correctness of hypotheses put forth by AI. Altogether, advances in technology, expanding knowledge, and the appropriate use of AI methods are preparing society to be able to address emerging diseases, such as pandemics, as well as conditions that are not effectively treated by currently existing therapeutics.

6. How do you expect the Tu Youyou Award to contribute to the advancement of natural product chemistry, medicinal chemistry, and human health over the coming years?

The Tu Youyou Award is potentially transformative for the broad fields of natural products science and medicinal chemistry as it brings a significantly increased level of visibility to these topics and their contributions to human health. It will be crucial to have excellent communication to news agencies, social media and other communication outlets so that the general public is informed and educated on the high impact of these natural product/medicinal chemistry contributions. This will bring increased funding, attract promising students, and generally enrich the interface of these fields with the health sector.

7. What message would you like to convey to the research community and the public during this open nomination phase?

This prize gives broad societal visibility to the role that natural products have had in shaping a majority of our current medicines, as well as understanding the life forms with whom we share the planet. Further, it recognizes a woman scientist working under sub-optimal conditions who could persevere and make discoveries of global impact. The prize and what it represents, therefore, inspires current and future generations to engage in the study of Nature and its relationship to Human Health, to overcome adversity, and to aspire to making one’s life impactful.

About the Tu Youyou Award

Established in 2016, the Tu Youyou Award seeks to honor those who excel in the fields of natural products chemistry and medicinal chemistry. This award offers a total prize of CHF 100,000, which will be equally divided among the winners if there is more than one, with each recipient receiving an award medal and a certificate.

The 2026 Tu Youyou Award is open for nominations until 31 October 2026. We encourage all eligible candidates to participate in this prestigious recognition, as this award not only honors individual achievement but also encourages further scientific exchange, exploration and discovery in critical areas of medicine.

If you are interested in participating, please visit the Tu Youyou Award website for more information on the nomination requirements.

Editor’s Choice Articles are selected based on suggestions from the Academic Editors of Biomedicines (ISSN: 2227-9059). The Editors select a small number of published articles that they consider to be particularly interesting to our readers or important in their respective fields of research. You are therefore invited to read our Editor’s Choice Articles, a curated list of high-quality articles published in Biomedicines in 2025. The full list of Editor’s Choice Articles can be viewed via the following link:
https://www.mdpi.com/journal/biomedicines/editors_choice.

1. “Animal Models for Studying Developmental Origins of Cardiovascular–Kidney–Metabolic Syndrome”
by You-Lin Tain, Ying-Jui Lin and Chien-Ning Hsu
Biomedicines 2025, 13(2), 452; https://doi.org/10.3390/biomedicines13020452
Available online: https://www.mdpi.com/2227-9059/13/2/452
Editor's highlight: “An interesting and updated selection of experimental studies in an important subject stimulating further investigations.”

2. “Enhancing Cardiovascular Risk Prediction with a Simplified Carotid IMT Protocol: Evidence from the IMPROVE Study”
by Fabrizio Veglia, Anna Maria Malagoni, Mauro Amato, Rona J. Strawbridge, Kai Savonen, Philippe Giral, Antonio Gallo, Matteo Pirro, Bruna Gigante, Per Eriksson et al.
Biomedicines 2025, 13(3), 584; https://doi.org/10.3390/biomedicines13030584
Available online: https://www.mdpi.com/2227-9059/13/3/584
Editor's highlight: “This manuscript shows results derived from the IMPROVE study, describing how carotid intima-media thickness is able to significantly improve the predictive capacity of cardiovascular risk scores.”

3. “Synergistic Effects of Green Nanoparticles on Antitumor Drug Efficacy in Hepatocellular Cancer”
by Mirela Claudia Rîmbu, Liliana Popescu, Mirela Mihăilă, Roxana Colette Sandulovici, Daniel Cord, Carmen-Marinela Mihăilescu, Mona Luciana Gălățanu, Mariana Panțuroiu, Carmen-Elisabeta Manea, Adina Boldeiu et al.
Biomedicines 2025, 13(3), 641; https://doi.org/10.3390/biomedicines13030641
Available online: https://www.mdpi.com/2227-9059/13/3/641
Editor's highlight: “I recommend this article because it reveals the synergistic antitumor effects of plant-derived nanoparticles synthesized from Melissa officinalis and Clematis vitalba when combined with conventional hepatic anticancer drugs. The extraction of nanoparticles from natural sources represents a novel and promising research direction with considerable potential for clinical applications. Moreover, the study systematically evaluates the toxicity of various nanoparticles and drugs, offering extensive data that serve as a valuable reference in the fields of biology and pharmaceuticals.”

4. “Personalized Nutrition in Chronic Kidney Disease”
by Nishigandha Pradhan, Jennifer Kerner, Luciana A. Campos and Mirela Dobre
Biomedicines 2025, 13(3), 647; https://doi.org/10.3390/biomedicines13030647
Available online: https://www.mdpi.com/2227-9059/13/3/647
Editor's highlight: “Dietary requirements in healthy individuals vary with age. Older individuals with chronic kidney disease who reduce their protein intake have worse nutritional status and physical performance than those who do not decrease their protein intake. This article nicely summarizes the personalized nutrition in chronic kidney disease.”

5. “Severe Asthma and Active SARS-CoV-2 Infection: Insights into Biologics”
by Sara Manti, Michela Leotta, Federica D’Amico, Simone Foti Randazzese, Giuseppe Fabio Parisi and Salvatore Leonardi
Biomedicines 2025, 13(3), 674; https://doi.org/10.3390/biomedicines13030674
Available online: https://www.mdpi.com/2227-9059/13/3/674
Editor's highlight: “The authors address current issues very diligently and with the utmost accuracy and up-to-dateness. I particularly like the article on COVID-19, as it serves to keep attention focused on the pandemic that has affected millions of people in recent years.”

6. “Application of the Human Proteome in Disease, Diagnosis, and Translation into Precision Medicine: Current Status and Future Prospects”
by Yawen Xie, Xiaoying Chen, Maokai Xu and Xiaochun Zheng
Biomedicines 2025, 13(3), 681; https://doi.org/10.3390/biomedicines13030681
Available online: https://www.mdpi.com/2227-9059/13/3/681
Editor's highlight: “This review provides a comprehensive and forward-looking overview of the role of human proteomics in advancing our understanding of disease mechanisms, biomarker discovery, and precision medicine. By bridging technological developments with clinical applications, the authors effectively highlight current achievements while also discussing key challenges that remain, emphasizing the significant translational potential of proteome-based approaches.”

7. “Investigating the Prognostic Role of Telomerase-Related Cellular Senescence Gene Signatures in Breast Cancer Using Machine Learning”
by Qiong Li and Hongde Liu
Biomedicines 2025, 13(4), 826; https://doi.org/10.3390/biomedicines13040826
Available online: https://www.mdpi.com/2227-9059/13/4/826
Editor's highlight: “Machine Learning (a form of AI) was used to achieve prognostic evaluation of breast cancer patients. Nineteen genes were identified for the study, and changes in their levels of expression was confirmed by biochemical and cell biological methods. The study was described well, and the data were analyzed competently. Overall, this is a nice paper and should be read by researchers and clinicians.  The authors are known for performing studies on various human diseases using similar approaches.”

8. “The Role of NK Cells in Cancer Immunotherapy: Mechanisms, Evasion Strategies, and Therapeutic Advances”
by Paula Morcillo-Martín-Romo, Javier Valverde-Pozo, María Ortiz-Bueno, Maurizio Arnone, Laura Espinar-Barranco, Celia Espinar-Barranco and María Eugenia García-Rubiño
Biomedicines 2025, 13(4), 857; https://doi.org/10.3390/biomedicines13040857
Available online: https://www.mdpi.com/2227-9059/13/4/857
Editor's highlight: “This is a well-structured and informative review that addresses a topic of considerable current interest in cancer immunotherapy. Its clear synthesis of NK-cell mechanisms, immune-evasion pathways, and therapeutic advances gives the manuscript strong clinical and translational relevance, with likely broad appeal to the journal’s readership.”

9. “Comprehensive Integrated Analysis Reveals the Spatiotemporal Microevolution of Cancer Cells in Patients with Bone-Metastatic Prostate Cancer”
by Yinghua Feng, Xiuli Zhang, Guangpeng Wang, Feiya Yang, Ruifang Li, Lu Yin, Dong Chen, Wenkuan Wang, Mingshuai Wang, Zhiyuan Hu et al.
Biomedicines 2025, 13(4), 909; https://doi.org/10.3390/biomedicines13040909
Available online: https://www.mdpi.com/2227-9059/13/4/909
Editor's highlight: “This is a high-impact original research paper. It presents a large-scale single-cell analysis of bone-metastatic prostate cancer, described as the largest dataset of its kind in this disease context, encompassing 124 samples and more than 600,000 cells, and identifies evolutionary patterns, a novel epithelial subpopulation, and metastasis-associated metabolic features. The scale, methodological currency, and disease relevance make it not only a useful data resource but also a compelling Editor’s Choice candidate.”

10. “Kidney Transplantation in Congenital Abnormalities of Kidney and Urinary Tract (CAKUT)”
by Silvio Maringhini and Lars Pape
Biomedicines 2025, 13(4), 932; https://doi.org/10.3390/biomedicines13040932
Available online: https://www.mdpi.com/2227-9059/13/4/932
Editor's highlight: “A review of a neglected but relevant group of patients who undergo kidney transplant, in which new protocols are needed.”

11. “A Systematic Review of Pneumonitis Following Treatment with Immune Checkpoint Inhibitors and Radiotherapy”
by Melina Yerolatsite, Nanteznta Torounidou, Anna-Lea Amylidi, Iro-Chrisavgi Rapti, George Zarkavelis, Eleftherios Kampletsas and Paraskevi V. Voulgari
Biomedicines 2025, 13(4), 946; https://doi.org/10.3390/biomedicines13040946
Available online: https://www.mdpi.com/2227-9059/13/4/946
Editor's highlight: “As a review paper, it addresses a highly consequential and increasingly common clinical problem at the intersection of immunotherapy and radiotherapy. The manuscript synthesizes evidence from 58 studies comprising 4889 patients and emphasizes risk factors, management challenges, and the need for predictive biomarkers and models. This review has clear value for a wide clinical audience.”

12. “Druggability Studies of Benzene Sulfonamide Substituted Diarylamide (E3) as a Novel Diuretic”
by Hang Zhang, Shuyuan Wang, Nannan Li, Yue Xu, Zhizhen Huang, Yukun Zhang, Jing Li, Yinglin Zuo, Min Li, Runtao Li et al.
Biomedicines 2025, 13(4), 992; https://doi.org/10.3390/biomedicines13040992
Available online: https://www.mdpi.com/2227-9059/13/4/992
Editor's highlight: “This manuscript identifies E3, a novel and potent inhibitor of urea transporters (UTs) that produces diuretic effects without causing electrolyte imbalance, which addresses a key limitation of many existing diuretics. The study provides strong mechanistic evidence to demonstrate that the compound acts primarily through UT-A1 inhibition. In addition, the compound shows good pharmacokinetics, metabolic stability, and safety in animal models, and it effectively improves hyponatremia, suggesting its potential as a new class of diuretics with therapeutic value.”

Editor’s Choice Articles are selected based on suggestions from the Academic Editors of Biomedicines (ISSN: 2227-9059). The Editors select a small number of published articles that they consider to be particularly interesting to our readers or important in their respective fields of research. You are therefore invited to read our Editor’s Choice Articles, a curated list of high-quality articles published in Biomedicines in 2025. The full list of Editor’s Choice Articles can be viewed via the following link: https://www.mdpi.com/journal/biomedicines/editors_choice.

1. “Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development”
by Whi-An Kwon, Ho Kyung Seo, Geehyun Song, Min-Kyung Lee and Weon Seo Park
Biomedicines 2025, 13(1), 86; https://doi.org/10.3390/biomedicines13010086
Available online: https://www.mdpi.com/2227-9059/13/1/86
Editor’s highlight: “I selected this article based on its high WoS total citations and its reasonable content.”

2. “Evidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)”
by Josep L. Clua-Espuny, Alba Hernández-Pinilla, Delicia Gentille-Lorente, Eulàlia Muria-Subirats, Teresa Forcadell-Arenas, Cinta de Diego-Cabanes, Domingo Ribas-Seguí, Anna Diaz-Vilarasau, Cristina Molins-Rojas, Meritxell Palleja-Millan et al.
Biomedicines 2025, 13(1), 119; https://doi.org/10.3390/biomedicines13010119
Available online: https://www.mdpi.com/2227-9059/13/1/119
Editor’s highlight: “This manuscript describes the results of a prospective cohort study performed to estimate the prevalence of device-detected atrial fibrillation and assess the feasibility and impact of systematic screening in routine primary care.”

3. “Differentiating Liver Metastases from Primary Liver Cancer: A Retrospective Study of Imaging and Pathological Features in Patients with Histopathological Confirmation”
by Laura Andreea Ghenciu, Mirela Loredana Grigoras, Luminioara Maria Rosu, Sorin Lucian Bolintineanu, Laurentiu Sima and Octavian Cretu
Biomedicines 2025, 13(1), 164; https://doi.org/10.3390/biomedicines13010164
Available online: https://www.mdpi.com/2227-9059/13/1/164
Editor’s highlight: “The paper was selected based on its quality in science and rationale.”

4. “Dietary Interventions and Physical Activity as Crucial Factors in the Prevention and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease”
by Paweł Rajewski, Jakub Cieściński, Piotr Rajewski, Szymon Suwała, Alicja Rajewska and Maciej Potasz
Biomedicines 2025, 13(1), 217; https://doi.org/10.3390/biomedicines13010217
Available online: https://www.mdpi.com/2227-9059/13/1/217
Editor’s highlight: “This is an interesting and well written review article describing in detail how dietary intervention and physical activity are crucial factors in the prevention and treatment of metabolic dysfunction-associated steatotic liver disease.”

5. “Butyrate Prevents Obesity Accompanied by HDAC9-Mediated Browning of White Adipose Tissue”
by Jing Yang, Guoli Li, Shan Wang, Mingqian He, Sijing Dong, Ting Wang, Binyin Shi, Patrick C. N. Rensen and Yanan Wang
Biomedicines 2025, 13(2), 260; https://doi.org/10.3390/biomedicines13020260
Available online: https://www.mdpi.com/2227-9059/13/2/260
Editor’s highlight: “This article shows how butyrate alleviated high-fat diet-induced obesity and promoted energy expenditure accompanied by brown adipose tissue activation and white adipose tissue browning.”

6. “Non-Invasive Retinal Biomarkers for Early Diagnosis of Alzheimer’s Disease”
by Snježana Kaštelan, Antonela Gverović Antunica, Velibor Puzović, Ana Didović Pavičić, Samir Čanović, Petra Kovačević, Pia Antonia Franciska Vučemilović and Suzana Konjevoda
Biomedicines 2025, 13(2), 283; https://doi.org/10.3390/biomedicines13020283
Available online: https://www.mdpi.com/2227-9059/13/2/283
Editor’s highlight: “Early diagnosis of Alzheimer's disease is important so that treatment can be immediately instituted. As stated in this report, diagnostic methods such as magnetic resonance imaging, computed tomography, positron emission tomography, and biomarker analysis in cerebrospinal fluid tend to be expensive and invasive. Blood-based biomarkers are available, but it takes time to get the results. Non-invasive retinal biomarkers for early diagnosis of Alzheimer’s disease may be the answers to this dilemma.”

7. “Phenotypes and Endotypes in Sarcoidosis: Unraveling Prognosis and Disease Course”
by Ilias C. Papanikolaou, Konstantinos Chytopoulos, Dimitrios Kaitatzis, Nikolaos Kostakis, Anastasios Bogiatzis, Paschalis Steiropoulos and Fotios Drakopanagiotakis
Biomedicines 2025, 13(2), 287; https://doi.org/10.3390/biomedicines13020287
Available online: https://www.mdpi.com/2227-9059/13/2/287
Editor’s highlight: “This interesting review article aimed to examine phenotypes and endotypes in sarcoidosis to unravel prognosis and disease course.”

8. “Cold vs. Room Temperature: A Comparative Analysis of Platelet Functionality in Cold Storage”
by Panagiotis V. Drossos, Sotirios P. Fortis, Alkmini T. Anastasiadi, Efthymia G. Pavlou, Andreas G. Tsantes, Gerasimos A. Spyratos, Effie G. Papageorgiou, Efrosyni G. Nomikou, Konstantinos E. Stamoulis, Georgios Dryllis et al.
Biomedicines 2025, 13(2), 310; https://doi.org/10.3390/biomedicines13020310
Available online: https://www.mdpi.com/2227-9059/13/2/310
Editor’s highlight: “This study tackles a longstanding and vital debate in transfusion medicine about the best storage conditions for platelets. The research offers strong evidence that cold-stored (CS) platelets surpass those stored at traditional room temperature (RT) in terms of hemostatic function and metabolic stability. Notably, the authors demonstrate that cold storage can preserve optimal platelet functionality for up to 15 days, representing a major advancement over the current standard. This could significantly reduce blood product waste and improve outcomes for trauma and surgical patients. The use of rotational thrombo-elastometry adds strong scientific credibility to their findings regarding clot formation and stability.”

9. “High-Throughput Microfluidic Production of Ultrasmall Lecithin Nanoliposomes for High-Efficacy Transdermal Delivery and Skin-Aging Treatment”
by Xiao Liang, Chan Lu, Fangqiao Zheng, Zhengyi Lan, Haoji Wang, Muhammad Shafiq, Xinxin Pan, Hangrong Chen and Ming Ma
Biomedicines 2025, 13(2), 322; https://doi.org/10.3390/biomedicines13020322
Available online: https://www.mdpi.com/2227-9059/13/2/322
Editor’s highlight: “The selected study focuses on the microfluidic-based synthesis of ultra-small nanoliposomes, an inherently interdisciplinary topic that bridges microfluidics, nanomedicine, and dermatological therapy, thereby appealing to a broad research audience. Importantly, it uncovers the critical role of these nanoliposomes in promoting skin drug penetration. The article is rich in content and stands out for its standardized formatting and strong writing quality compared to others.”

10. “The Role of Early Risk Factor Modification and Ablation in Atrial Fibrillation Substrate Remodeling Prevention”
by Ioanna Koniari, Maria Bozika, Kassiani-Maria Nastouli, Dimitra Tzegka, Anastasios Apostolos, Dimitrios Velissaris, Georgios Leventopoulos, Angelos Perperis, Nicholas G. Kounis, Grigorios Tsigkas et al.
Biomedicines 2025, 13(2), 405; https://doi.org/10.3390/biomedicines13020405
Available online: https://www.mdpi.com/2227-9059/13/2/405
Editor’s highlight: “This is an interesting and well written review article which evaluates the role of early risk factor modification and ablation in atrial fibrillation substrate remodeling prevention.”

11. “Evolution of Light-Sensitive Proteins in Optogenetic Approaches for Vision Restoration: A Comprehensive Review”
by Kamil Poboży, Tomasz Poboży, Paweł Domański, Michał Derczyński, Wojciech Konarski and Julia Domańska-Poboża
Biomedicines 2025, 13(2), 429; https://doi.org/10.3390/biomedicines13020429
Available online: https://www.mdpi.com/2227-9059/13/2/429
Editor’s highlight: “The paper focuses on how to treat patients whose eyesight is compromised. This is an interesting and important field of research. Optogenetics is relatively new and is a provocative approach, which is still in its infancy. This review provides an up-to-date summary of this new field. The review is organized nicely to present the progress of the field. There are many challenges, but the approach may be clinically feasible. The authors cite the latest papers published on the topic.”

12. “Antitumor Potential of Different Treatment Approaches Using Cold Atmospheric Pressure Plasma on Oral Squamous Cell Carcinoma Models: In Vitro Study”
by Ognjan Pavlović, Miloš Lazarević, Aleksandar Jakovljević, Nikola Škoro, Nevena Puač, Slavko Mojsilović and Maja Miletić
Biomedicines 2025, 13(2), 443; https://doi.org/10.3390/biomedicines13020443
Available online: https://www.mdpi.com/2227-9059/13/2/443
Editor’s highlight: “This manuscript describes an interesting study that shows a promising avenue for the application of cold atmospheric plasma as a therapeutic option, either as standalone treatment or in combination with cisplatin.”

Editor’s Choice Articles are selected based on suggestions from the Academic Editors of Biomedicines (ISSN: 2227-9059). The Editors select a small number of published articles that they consider to be particularly interesting to our readers or important in their respective fields of research. You are therefore invited to read this curated list of high-quality articles published in Biomedicines in 2025. The full list of Editor’s Choice Articles can be viewed via the following link:

https://www.mdpi.com/journal/biomedicines/editors_choice.

1. “Advancing Head and Neck Cancer Therapies: From Conventional Treatments to Emerging Strategies”
by Aleksandra Mordzińska-Rak, Ilona Telejko, Grzegorz Adamczuk, Tomasz Trombik, Andrzej Stepulak and Ewa Błaszczak
Biomedicines 2025, 13(5), 1046; https://doi.org/10.3390/biomedicines13051046
Available online: https://www.mdpi.com/2227-9059/13/5/1046
Editor’s highlight: “An interesting retrospective review on head and neck cancer therapy options with a focus on recent advancements such as nanomedicine and proteolysis-targeting chimera (PROTAC)-based strategies.”

2. “The IL-6/JAK/STAT3 Axis in Cholangiocarcinoma and Primary Sclerosing Cholangitis: Unlocking Therapeutic Strategies Through Patient-Derived Organoids”
by Corinna Boden, Laura K. Esser, Leona Dold, Bettina Langhans, Taotao Zhou, Dominik J. Kaczmarek, Maria A. Gonzalez-Carmona, Tobias J. Weismüller, Glen Kristiansen, Jörg C. Kalff et al.
Biomedicines 2025, 13(5), 1083; https://doi.org/10.3390/biomedicines13051083
Available online: https://www.mdpi.com/2227-9059/13/5/1083
Editor’s highlight: “These authors utilized a patient-derived organoid model for successful testing of therapeutic strategies against primary sclerosing cholangitis and liver tumors, including the use of JAK inhibitors and chemotherapy modalities.”

3. “Current Status and Future Perspectives of Nuclear Medicine in Prostate Cancer from Imaging to Therapy: A Comprehensive Review”
by Joohee Lee and Taejin Kim
Biomedicines 2025, 13(5), 1132; https://doi.org/10.3390/biomedicines13051132
Available online: https://www.mdpi.com/2227-9059/13/5/1132
Editor’s highlight: “Prostate cancer remains a high-interest disease area, and the review addresses a rapidly evolving field centered on radioligand imaging and theranostics. The manuscript highlights the expanding role of PSMA- and GRPR-targeted tracers in diagnosis, staging, and radionuclide therapy, making it both timely and broadly relevant to oncologists, nuclear medicine specialists, and translational investigators. Its readership potential is likely substantial.”

4. “Oligodendroglioma: Advances in Molecular Mechanisms and Immunotherapeutic Strategies”
by Yongxin Zhao, Yan Yu, Weizhi Chen, Xiaojun Zhang, Jing Lv and Heping Zhao
Biomedicines 2025, 13(5), 1133; https://doi.org/10.3390/biomedicines13051133
Available online: https://www.mdpi.com/2227-9059/13/5/1133
Editor’s highlight: “This article addresses current issues very diligently and with the utmost accuracy and currentness. Talking about brain tumors makes sense today, because these threats have not yet been eradicated.”

5. “Safety and Efficacy of Regorafenib and 5-Fluorouracil Combination Therapy in Refractory Metastatic Colorectal Cancer After Third-Line Treatment: An Institutional Experience”
by Maen Abdelrahim, Abdullah Esmail, Ebtesam Al-Najjar, Bayan Khasawneh, Godsfavour Umoru, Waseem Abdelrahim, Karen Abboud and Veronica B. Ajewole
Biomedicines 2025, 13(5), 1151; https://doi.org/10.3390/biomedicines13051151
Available online: https://www.mdpi.com/2227-9059/13/5/1151
Editor’s highlight: “This compact study revealed that an unprecedented combination of regorafenib and 5-fluorouracil can be a suitable treatment option for patients with refractory metastatic colorectal carcinoma.”

6. “Emerging Epigenetic Therapies for the Treatment of Cardiac Fibrosis”
by Nerea Garitano, Laura Pilar Aguado-Alvaro and Beatriz Pelacho
Biomedicines 2025, 13(5), 1170; https://doi.org/10.3390/biomedicines13051170
Available online: https://www.mdpi.com/2227-9059/13/5/1170
Editor’s highlight: “This article presents a clear and well-structured synthesis of the epigenetic mechanisms underlying cardiac fibrosis and the therapeutic opportunities emerging from these insights. By connecting molecular regulatory pathways with developing pharmacological strategies, the authors offer a timely and clinically relevant perspective that may help guide future antifibrotic research and therapy development.”

7. “Stem Cell Therapy for Myocardial Infarction Recovery: Advances, Challenges, and Future Directions”
by Nicholas T. Le, Matthew W. Dunleavy, William Zhou, Sumrithbir S. Bhatia, Rebecca D. Kumar, Suyin T. Woo, Gonzalo Ramirez-Pulido, Kaushik S. Ramakrishnan and Ahmed H. El-Hashash
Biomedicines 2025, 13(5), 1209; https://doi.org/10.3390/biomedicines13051209
Available online: https://www.mdpi.com/2227-9059/13/5/1209
Editor’s highlight: “This provides an up-to-date review of an important medical field.”

8. “Cardiac Amyloidosis: A Narrative Review of Diagnostic Advances and Emerging Therapies”
by Dana Emilia Movila, Alexandru Catalin Motofelea, Dragos Cozma, Oana Albai, Alexandra Christa Sima, Minodora Andor, Tudor Ciocarlie and Simona Ruxanda Dragan
Biomedicines 2025, 13(5), 1230; https://doi.org/10.3390/biomedicines13051230
Available online: https://www.mdpi.com/2227-9059/13/5/1230
Editor’s highlight: “This is a well-written review article describing diagnostic advances and emerging therapies in cardiac amyloidosis.”

9. “Spatial Heterogeneity of Intratumoral Microbiota: A New Frontier in Cancer Immunotherapy Resistance”
by Qiwen Tan, Xiongjing Cao, Falong Zou, Hanwenchen Wang, Lijuan Xiong and Shenghe Deng
Biomedicines 2025, 13(5), 1261; https://doi.org/10.3390/biomedicines13051261
Available online: https://www.mdpi.com/2227-9059/13/5/1261
Editor’s highlight: “This article comprehensively covers the latest topics and is expected to be of interest to many cancer researchers.”

10. “Exosomal Protein Biomarkers in Arthritis: Deciphering the Inflammatory Profiles of RA and OA”
by Claudia M. Brenis Gómez, Chamaida Plasencia-Rodríguez, Marta Novella-Navarro, Ana Martínez-Feito, Alejandro Balsa, Enrique Calvo-Aranda and Borja Hernández-Breijo
Biomedicines 2025, 13(6), 1283; https://doi.org/10.3390/biomedicines13061283
Available online: https://www.mdpi.com/2227-9059/13/6/1283
Editor’s highlight: “This study uses advanced proteomic analysis to identify specific biomarkers in serum-derived extracellular vesicles (EVs) that differentiate Rheumatoid Arthritis (RA) from Osteoarthritis (OA). It provides a deeper understanding of the distinct pathophysiological mechanisms involved in these common diseases. The study emphasizes the potential of using exosomes as noninvasive “liquid biopsy” biomarkers, which could enable earlier detection and more personalized treatment options for patients with rheumatic diseases. By identifying specific inflammatory signatures—such as increased IL-6 signaling in RA versus ROCK2 signaling in OA—it paves the way for targeted therapeutic strategies.”

11. “Long-Term Outcomes After High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiotherapy in Very High-Risk Prostate Cancer: A 24-Year Follow-Up”
by Pedro J. Prada Gómez, Ana L. Rivero Pérez, Joaquín Carballido Rodríguez, Javier Anchuelo Latorre, Rosa Fabregat Borrás, Marina Gutiérrez Ruiz, Cristina Rodríguez-Acosta Caballero, Carlos F. Carrascal Gordillo, Maria P. Galdós Barroso and Paola A. Navarrete Solano
Biomedicines 2025, 13(6), 1310; https://doi.org/10.3390/biomedicines13061310
Available online: https://www.mdpi.com/2227-9059/13/6/1310
Editor’s highlight: “A striking 24-year follow-up assessing the long-term oncological outcomes and toxicity profiles in patients with localized very-high-risk prostate cancer (VHR PCa) treated with a combination of brachytherapy and pelvic external beam radiation therapy (EBRT).”

12. “A Deep Learning Methodology for Screening New Natural Therapeutic Candidates for Pharmacological Cardioversion and Anticoagulation in the Treatment and Management of Atrial Fibrillation”
by Tim Dong, Rhys D. Llewellyn, Melanie Hezzell and Gianni D. Angelini
Biomedicines 2025, 13(6), 1323; https://doi.org/10.3390/biomedicines13061323
Available online: https://www.mdpi.com/2227-9059/13/6/1323
Editor’s highlight: “This study presents a new high-performing model under low-resource settings that identified new natural therapeutic candidates for pharmacological cardioversion and anticoagulation as part of a case study.”

World Malaria Day, observed annually on 25 April, celebrates the importance of raising awareness of malaria and the preventive efforts to control the disease, with the ultimate goal of eradicating malaria worldwide.  With the development of new vaccines, treatments, malaria control tools, and pioneering technologies, ending malaria within our lifetime has become a real possibility.

In recognition of World Malaria Day, MDPI reaffirms its commitment to advancing cutting-edge and interdisciplinary research. Through open access publishing, we support the dissemination of discoveries in Public Health & Healthcare, Medicine & Pharmacology, Biology, Life Sciences, and related fields —ensuring knowledge is accessible and empowering researchers to contribute to the next generation of scientific and technological breakthroughs.

MDPI established the Tu Youyou Award in 2016 to honor Professor Tu Youyou’s remarkable contributions to human health and acknowledge exceptional scholars committed to the research fields of natural product and medicinal chemistry.

Prize:

• CHF 100,000 (to be divided equally should multiple recipients be awarded);
• An award medal and a certificate.

Nomination Deadline: 31 October 2026.

For further information, please visit the Tu Youyou Award website (https://tuyouyouprize.org/).
For any inquiries, please contact the Tu Youyou Award Team at tuyouyouaward@mdpi.com.

Prof. Eleni Patsoula, School of Public Health, University of West Attica, Athens, Greece	Prof. Oleksii Skorokhod, Department of Life Sciences and Systems Biology, University of Turin, Italy	Prof. Dr. Toshio Hattori, Roken Akanpe Nursing Home, Kurashiki, Okayama, Japan
Dr. Kostas Eleftheratos, School of Health Systems and Public Health, University of Pretoria, Institute for Sustainable Malaria Control (UP ISMC), South Africa	Dr. Michael Eisenhut, Cochrane Collaboration, UK

Register for this webinar for free here!

“Diagnostic Accuracy of Utilizing Artificial Intelligence for Malaria Diagnostic: A Systematic Review and Meta-Analysis”
by Icha Farihah Deniyati Faratisha, Khadijah Cahya Yunita,  Hanifa Rizky Rahmawati, Loeki Enggar Fitri, Nuning Winaris and Lailil Muflikah
Infect. Dis. Rep. 2026, 18(1), 11; https://doi.org/10.3390/idr18010011

“Enduring Warning: A Holistic Comparison of the Establishment and Spread of P. falciparum Evolutionary Lineage Malaria in Ancient Rome and the Threat of Zoonotic P. knowlesi Malaria in Modern Southeast Asia”
by Mark Orsag, Giovanni Meledandri, Amanda McKinney and Melissa Clouse
Zoonotic Dis. 2025, 5(4), 34; https://doi.org/10.3390/zoonoticdis5040034

“Evolutionary Trajectory of Plasmodium falciparum: From Autonomous Phototroph to Dedicated Parasite”
by Damian Pikor, Mikołaj Hurla, Alicja Drelichowska and Małgorzata Paul
Biomedicines 2025, 13(9), 2287; https://doi.org/10.3390/biomedicines13092287

“Correlation of Inflammatory Biomarkers and IgG4 Antibodies with Malaria in Cameroon’s Buea Municipality Children”
by Jerome Nyhalah Dinga, Flora Ayah, Emmanuel Fondungallah Anu, Haowen Qin, Stanley Dobgima Gamua, Anthony Kukwah Tufon, Magloire Essissima Amougou and  Rameshbabu Manyam
Diseases 2025, 13(4), 123; https://doi.org/10.3390/diseases13040123

“Alterations in von Willebrand Factor Levels in Patients with Malaria: A Systematic Review and Meta-Analysis of Disease Severity”
by Suriyan Sukati, Rujikorn Rattanatham, Frederick Ramirez Masangkay, Ching-Ping Tseng and Manas Kotepui
Medicina 2025, 61(4), 767; https://doi.org/10.3390/medicina61040767

“Genetic Diversity of Potential Drug Resistance Markers in Plasmodium vivax Isolates from Panama, Mesoamerica”
by Vanessa Vásquez, Ana María Santamaría, Dianik Moreno, Fergie Ruíz, Chystrie A. Rigg, Luis F. Chaves and José E. Calzada
Pathogens 2025, 14(3), 231; https://doi.org/10.3390/pathogens14030231

“Duplication of a Type-P5B-ATPase in Laverania and Avian Malaria Parasites and Implications About the Evolution of Plasmodium”
by Mark F. Wiser
Parasitologia 2025, 5(1), 6; https://doi.org/10.3390/parasitologia5010006

“Identification of Malaria-Selective Proteasome β5 Inhibitors Through Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulation”
by Muhammad Yasir, Jinyoung Park, Eun-Taek Han, Jin-Hee Han, Won Sun Park and Wanjoo Chun
Int. J. Mol. Sci. 2024, 25(22), 11881; https://doi.org/10.3390/ijms252211881

“Antimalarial Mechanisms and Resistance Status of Artemisinin and Its Derivatives”   
by Dan Zheng,  Tingting Liu, Shasha Yu, Zhilong Liu, Jing Wang and Ying Wang
Trop. Med. Infect. Dis. 2024, 9(9), 223; https://doi.org/10.3390/tropicalmed9090223

“Sensitivity Assessment of a Multiplex and Real-Time PCR Protocols for the Detection of Malaria in External Quality Control Samples in the Malaria Reference Center in Greece”
by Nikolaos Tegos, Christos Goumenopoulos, Anastasia Mpimpa, Vasilios Papavasilopoulos, Stavroula Beleri and Eleni Patsoula
Parasitologia 2024, 4(2), 150-161; https://doi.org/10.3390/parasitologia4020013

“Targeting Plasmodium Life Cycle with Novel Parasite Ligands as Vaccine Antigens”
by Shan Khan, Manas Paresh Patel, Aleem Damji Patni and Sung-Jae Cha
Vaccines 2024, 12(5), 484; https://doi.org/10.3390/vaccines12050484

“Advances in Microparasite Research”  Guest Editors: Dr. Sofia Nolasco and Dr. Inês L. S. Delgado   Submission deadline: 31 July 2026	“Malaria in a Changing World” Guest Editors: Dr. Harry Tagbor and Dr. Luiz Shozo Ozaki Submission deadline: 20 August 2026
“Genetic and Molecular Research on the Malaria Parasite” Guest Editors: Prof. Dr. Hajime Hisaeda and Dr. Takashi Imai Submission deadline: 20 September 2026	“Advances in Tools for Battling Malaria” Guest Editors: Dr. Wenn-Chyau Lee and Dr. Meng Yee Lai Submission deadline: 31 December 2026

Dr. Vasileios Papadopoulos is one of the winners of the Outstanding Reviewer Award.

Dr. Vasileios Papadopoulos is an internist, molecular biologist, and geneticist. He serves as Assistant Professor of Anatomy at Democritus University of Thrace and concurrently works as a consultant at AKESIOS Dialysis Center in Xanthi, Greece. He previously served as Head of the Department of Internal Medicine at Xanthi General Hospital and as Lecturer in Internal Medicine at Democritus University of Thrace. His academic and clinical interests include evidence-based anatomy, biostatistics, internal medicine, clinical nephrology, hematology, and clinical epidemiology. He has authored or co-authored more than 100 publications in PubMed-indexed journals.

The following is a short interview with Dr. Vasileios Papadopoulos:

1. Can you share your current research direction and latest progress?

My current research focuses on evidence-based anatomy, mainly through prevalence meta-analyses of anatomical variants. I am also interested in further developing the methodological framework of this field, particularly regarding reporting bias, small-study effects, and other sources of distortion in pooled estimates. My recent work aims to make evidence-based anatomy more rigorous, transparent, and clinically useful.

2. Could you share with us your feelings about winning the award? What does this award mean to your academic career?

I sincerely thank the Editorial Board of Biomedicines for this distinction and honor. Having completed 16 reviews for the journal so far, I see this award both as an acknowledgment of my effort and as a commitment to continue serving peer review with the same sense of responsibility. For my academic career, it is a meaningful recognition that careful, timely, and constructive reviewing remains an important scholarly contribution.

3. What role do you think reviewers play in the process of paper publication?

Reviewers should serve as rigorous but constructive scientific guardians. Their role is not only to identify weaknesses, omissions, or possible misconduct, but also to help authors improve manuscripts that are scientifically worthwhile. Good reviewing should promote clarity, methodological soundness, and integrity while discouraging superficiality, carelessness, and fraud.

4. How do you balance the comprehensiveness and efficiency of review?

I try to be scientifically accurate and precise while explaining my comments in clear and simple language. My main principle is to ensure that the purpose of a manuscript is clear, the methods are correct and reproducible, and the results are understandable to the average scientist in the field. 

5. In your opinion, what key qualities should an excellent manuscript have? From what perspectives will you help authors improve the quality of their papers?

An excellent manuscript should combine originality with a clear scientific question, sound methodology, proper data collection and analysis, and a logically coherent conclusion. Its discussion should be substantive, educational, and directly supported by the findings. In my reviews, I try to help authors improve conceptual clarity, methodological rigor, and transparency in reporting, data interpretation, and the overall educational value of the paper.

6. How do you hope that journals and publishers can further support reviewers’ work?

Journals and publishers could further support reviewers by offering incentives that are reinvested in research, such as publication discounts or fee waivers. Many reviewers are also active researchers, so this kind of support has practical value. Personally, I am not in favor of direct financial payments or gifts that are not linked to research activity or to the scientific mission of the journal. 

7. Please briefly describe your experience with our services and journals so far?

Overall, my experience with your services and journals has been honest and constructive. There have been instances in which I disagreed with the final assessment of a manuscript’s scientific value, but in such cases, the broader perspective and experience of the Editor-in-Chief naturally prevail. In general, my interactions with the journal have been professional and productive.

Biomedicines (ISSN: 2227-9059, IF 3.9) is proud to announce its role as a media partner for the Barcelona Blood–Brain Barrier Conference 2026. This sponsorship highlights the journal’s commitment to supporting the scholarly community and engaging in critical industry discussions with the public.

Date: 3–5 November 2026
Location: Barcelona, Spain
Website: https://premc.org/blood-brain-barrier-conference/

The Barcelona Blood–Brain Barrier Conference 2026 will bring together scientists from across the globe to discuss emerging topics in BBB physiology, pathology and translational research. This interdisciplinary event will incorporate neuroscience, vascular biology, protein engineering, bioengineering, and nanomedicine to provide a unique platform to foster collaboration and address challenges shaping the future of this field.
About the Media Partner: Biomedicines

Biomedicines is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. As the media partner of the Barcelona Blood–Brain Barrier Conference 2026, Biomedicines will feature the conference highlights, research spotlights, and author opportunities for attendees and the blood–brain barrier research community within the broader field of biomedicines.

We look forward to seeing you at the Barcelona Blood–Brain Barrier Conference 2026.

MDPI is excited to announce a special webinar in celebration of World Malaria Day on 24 April 2026. This event will promote public understanding of malaria diagnosis and prevention, as well as highlight the development of pioneering technologies that have made malaria elimination possible.

Date: 24 April at 10:00 a.m. CEST | 4:00 p.m. CST Asia
Webinar ID: 847 7074 5022
Webpage: https://sciforum.net/event/MWMDW

Register now for free:

Program:

After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic and institutional email addresses will be prioritized.

Unable to attend? Register anyway, and we will let you know when the recording is available to watch.

Keynote Speakers:

• Prof. Eleni Patsoula, School of Public Health, University of West Attica, Athens, Greece;
• Prof. Oleksii Skorokhod, Department of Life Sciences and Systems Biology, University of Turin, Via Accademia Albertina 13, 10123 Turin, Italy;
• Prof. Dr. Toshio Hattori, Roken Akanpe Nursing Home, Kurashiki, Okayama, Japan;
• Dr. Ashley Burke, School of Health Systems and Public Health, University of Pretoria Institute for Sustainable Malaria Control (UP ISMC), South Africa;
• Dr. Michael Eisenhut, Cochrane Collaboration, UK.

Relevant Special Issues:
“Advances in Microparasite Research”
Guest Editors: Dr. Sofia Nolasco and Dr. Inês L. S. Delgado
Submission deadline: 31 July 2026

“Malaria in a Changing World”
Guest Editors: Dr. Harry Tagbor and Dr. Luiz Shozo Ozaki
Submission deadline: 20 August 2026

“Genetic and Molecular Research on the Malaria Parasite "
Guest Editors: Prof. Dr. Hajime Hisaeda and Dr. Takashi Imai
Submission deadline: 20 September 2026

“Advances in Tools for Battling Malaria”
Guest Editors: Dr. Wenn-Chyau Lee and Dr. Meng Yee Lai
Submission deadline: 31 December 2026

“Recent Advances in Malaria Vaccine Development—2nd Edition”
Guest Editors: Dr. Ahmad Rushdi Shakri and Dr. Dipak Raj
Submission deadline: 31 December 2026

Prof. Dr. Mary Garvey is the author of the Editor’s Choice Article entitled “Intestinal Dysbiosis: Microbial Imbalance Impacts on Colorectal Cancer Initiation, Progression and Disease Mitigation” published in Biomedicines (ISSN: 2227-9059).

Mary Garvey completed her MSc in veterinary epidemiology and public health at the University of London and her PhD in toxicology at the Technological University of the Shannon, Athlone Campus. She is the Principal Investigator of the PEM Centre Team and a lecturer at the Atlantic Technological University. Her research interests mainly focus on Toxicology, Microbiology, and Veterinary Science.

We interviewed Prof. Dr. Mary Garvey about her current research and future directions:

1. Congratulations on your published paper! Why did you choose the journal Biomedicines as a platform for publishing your work, and how was your experience?
I have published many papers in Biomedicines. It is a good jornal with a good impact factor. I find it to be an easy process with access to readers in my areas such as microbiology and toxicology, disease aetilogy and treatment.

2. Can you tell us a little bit about yourself and your current research?
I hold a PhD in toxicology and a Master’s degree in veterinay science. Currently I am isolating some waterborne pathogens releveant to the WHO priorty pathogen list and testing for AMR.

3. Please share what inspired your research.
A love of sicence and biology in general. I am fascinated by the aetiology of disease and pathogenesis of microbial species. And by the releationship between commensal organisms and disease in humans.

4. How did feedback during your research influence your direction?
Feedback helps direct the research in relevant areas and provides necessary instruction to keep the topic on point.

5. What role did you play in your research team, and how did teamwork affect the paper's outcome?
I am usually the leader of the team. Teamwork makes the paper’s formulation more smooth.